Pharmacokinetic and bioequivalence study of imidocarb in sheep by high performance liquid chromatography

The present study was undertaken to evaluate the pharmacokinetics and bioequivalence of two formulations of Imidocarb (Imidol® and Imizol®) @ 2.0 mg/kg b.w. IM in sheep. The plasma concentration of Imidocarb was determined by High Performance Liquid Chromatography (HPLC). The decay in plasma concentration of drug was biexponential in sheep. The C_max value of 2.448 and 1.785 pg.ml^-1 was obtained at T_max of 0.296 and 0.274 h, following IM administration of Imidol® and Imizol®, respectively. The elimination half life (ßt_1/2), volume of distribution (V1_F) and area under the curve (AUC) were calculated as 10.48 hr, 0.66 L.kg⁻¹, 12.36 ig.mM.hr and 11.66h, 0.96 L.kg⁻¹, 9.326 ig.mM.hr for Imidol® and Imizol®, respectively. On the basis of present pharmacokinetic study, the IM dosage regimen of 0.4, 2.2 and 12.2 mg.kg⁻¹ was calculated as priming dose and 0.34, 2.18 and 12.2 mg.kg⁻¹ as maintenance dose for sheep at dosing intervals of 24, 48 and 72 hr, respectively. Bioequivalence of Imidol® with respect to Imizol® in sheep was 132.6% following IM administration.